These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 30418554)

  • 1. Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.
    Edgeworth JD; Merante D; Patel S; Young C; Jones P; Vithlani S; Wyncoll D; Roberts P; Jones A; Den Nagata T; Ariyasu M; Livermore DM; Beale R
    Clin Infect Dis; 2019 May; 68(11):1932-1934. PubMed ID: 30418554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report.
    Stevens RW; Clancy M
    Pharmacotherapy; 2019 Nov; 39(11):1113-1118. PubMed ID: 31550054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prosthetic valve endocarditis caused by Pseudomonas aeruginosa with variable antibacterial resistance profiles: a diagnostic challenge.
    Gürtler N; Osthoff M; Rueter F; Wüthrich D; Zimmerli L; Egli A; Bassetti S
    BMC Infect Dis; 2019 Jun; 19(1):530. PubMed ID: 31208366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient.
    Alamarat ZI; Babic J; Tran TT; Wootton SH; Dinh AQ; Miller WR; Hanson B; Wanger A; Gary JL; Arias CA; Pérez N
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31871075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?
    Shields RK
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
    Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y
    J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane-tazobactam for the treatment of ventilator-associated infections by colistin-resistant Pseudomonas aeruginosa.
    Álvarez Lerma F; Muñoz Bermudez R; Grau S; Gracia Arnillas MP; Sorli L; Recasens L; Mico García M
    Rev Esp Quimioter; 2017 Jun; 30(3):224-228. PubMed ID: 28361526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prosthetic valve endocarditis caused by metallo-beta-lactamase-producing Pseudomonas aeruginosa.
    Kato Y; Ohashi H; Tsutsumi Y; Murakami T; Takahashi Y
    J Card Surg; 2009; 24(3):347-9. PubMed ID: 19438796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-nosocomial healthcare-associated left-sided Pseudomonas aeruginosa endocarditis: a case report and literature review.
    Hagiya H; Tanaka T; Takimoto K; Yoshida H; Yamamoto N; Akeda Y; Tomono K
    BMC Infect Dis; 2016 Aug; 16(1):431. PubMed ID: 27543116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.
    Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
    Int J Antimicrob Agents; 2018 Feb; 51(2):206-212. PubMed ID: 29111435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of carbapenem-resistant
    Canton R; Doi Y; Simner PJ
    Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1077-1094. PubMed ID: 35502603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infective Endocarditis Associated with Implantable Cardiac Device by Metallo-β-Lactamase-Producing Pseudomonas aeruginosa, Successfully Treated with Source Control and Cefiderocol Plus Imipenem.
    Tascini C; Antonelli A; Pini M; De Vivo S; Aiezza N; Bernardo M; Di Luca M; Rossolini GM
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0131322. PubMed ID: 36815774
    [No Abstract]   [Full Text] [Related]  

  • 17. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resurgence of Pseudomonas endocarditis in Detroit, 2006-2008.
    Reyes MP; Ali A; Mendes RE; Biedenbach DJ
    Medicine (Baltimore); 2009 Sep; 88(5):294-301. PubMed ID: 19745688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
    MacVane SH; Pandey R; Steed LL; Kreiswirth BN; Chen L
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
    Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
    Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.